Levetiracetam Almus

Levetiracetam, the active ingredient in Levetiracetam Almus, is an antiepileptic presented as an oral tablet for oral use. It treats partial‑onset and generalized tonic‑clonic seizures in patients requiring seizure control.

GNH USA supplies Levetiracetam Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug used to manage seizure disorders.

Partial‑onset seizures: reduces the frequency of focal seizures. Generalized tonic‑clonic seizures: helps control convulsive episodes. Epilepsy (adjunct therapy): used alongside other agents to achieve broader seizure control.

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired. - Headache: mild to moderate pain. - Irritability: mood changes or agitation. - Nausea: occasional stomach upset. - Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood disorders: depression or suicidal thoughts. - Hematologic changes: low blood cell counts. - Hepatic dysfunction: elevated liver enzymes. - Severe skin reactions: Stevens‑Johnson syndrome. - Multi‑organ hypersensitivity: systemic inflammatory response.

Before initiating therapy, consider the following safety measures.

Renal function: adjust dose if creatinine clearance is reduced. Pregnancy status: evaluate risk‑benefit, as data are limited. Concomitant CNS depressants: monitor for enhanced sedation. Psychiatric history: watch for mood changes or aggression. Driving and operating machinery: caution until individual response is known. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: can lower levetiracetam exposure. - Phenytoin: may decrease levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: additive central nervous system depression. - Sedative antihistamines: increased drowsiness. - Opioids: enhanced respiratory depression risk. - Other antiepileptics (e.g., valproate): monitor seizure control and side‑effect profile.